Research published by the American Heart Association found that pre-treated patients with off-label selective vasodilator drugs are more likely to develop right-sided heart failure after LVAD implantation, increasing their risk of worse outcomes.
The American Heart Association and the Heart Failure Society of America issue a statement on managing both conditions, highlighting lifestyle modifications and multidisciplinary care teams. The guidelines emphasize the importance of coordinated treatment to improve patient outcomes.
A survey shows a wide variation in UK heart failure care, with some areas having fewer than seven nurses per 1,600 patients. Many services lack administrative support and mental health professionals, despite updated guidelines recommending best practice for diagnosis and management.
A new blood test that measures multiple proteins could provide a more accurate diagnosis of heart failure, allowing for earlier treatment and improved outcomes. Researchers are now collecting further samples to confirm the accuracy of this protein-based test.
A recent study by Dr. Ganesh Halade and colleagues found that lipoxygenase deficiency delays heart failure progression and improves survival in mice. The researchers discovered that epoxyeicosatrienoic acids facilitate cardiac healing after a heart attack, reducing diabetes risk biomarkers and altering plasma metabolic signaling.
Patients with chronic heart failure are more likely to adopt lifestyle advice when accompanied by family members, according to a new study. The study found that nearly 48% of patients did no physical activity and 25% never adhered to fluid restrictions.
A study found that elderly patients with heart failure who visit a pharmacist weekly are more likely to take their medications and be active, resulting in improved quality of life. The intervention increased adherence by 86% compared to usual care.
Patients with stable chronic heart failure can safely discontinue diuretics without increased dyspnoea or reuse of the medication. The ReBIC-1 trial found no significant differences in symptom relief between patients who stopped and those who continued taking furosemide.
A new study reveals that women undergoing fertility treatment are at a higher risk of peripartum cardiomyopathy (PPCM), a life-threatening condition. PPCM affects about one in 1,000 pregnant women worldwide and is characterized by an enlarged and weak heart, leading to symptoms such as shortness of breath and swelling.
A study found that biomarkers like midregional proadrenomedullin and bio-adrenomedullin can predict mortality risk in acute heart failure patients. Patients with these biomarker levels above the median had significantly lower survival if not receiving diuretics at discharge.
Researchers found that being an occupant in a motor vehicle accident increases the risk of heart failure or stroke in older adults. The study used U.S. and Danish hospitalization data to confirm these findings.
Researchers identified a protein called gravin as key to regulating beta-adrenergic receptor expression on heart cells. Elevated adrenaline levels in heart failure desensitize receptors, reducing heart function. Researchers seek to develop treatment targeting this mechanism.
A study found that UK heart failure patients receive suboptimal care, with gaps in screening, follow-up, and medication doses disproportionately affecting women and older individuals. The study suggests improvements are needed in health services design to support high-quality care.
A UK study of 93,000 adults with heart failure reveals diagnostic tests, drug prescriptions, and follow-up patterns are suboptimal, particularly for women and those over 75 years old. The research highlights the need for improved care systems to address these gaps in chronic disease management.
A novel therapeutic approach occluding the superior vena cava shows promise in reducing pressure and volume in heart failure patients. The treatment improves cardiac filling pressures and function without affecting systemic blood pressure or output.
A study of over 8,000 participants found that elevated troponin I levels are associated with cardiac outcomes like heart attacks and fatal coronary disease. Adding troponin I to a risk prediction model improves accuracy in predicting heart failure risk, highlighting the potential for improved treatment strategies.
A machine learning algorithm using eight variables has been developed to predict sudden cardiac death and heart failure death in heart failure patients. The study found a high accuracy rate of 0.87 for predicting all events, and 0.74 and 0.91 for arrhythmic events and heart failure death respectively.
A study of over 4,500 participants found that those under 75 who closely followed the DASH diet had a significantly lower risk of developing heart failure. The research suggests that the DASH diet can reduce heart failure risk by almost half, making it a promising element in primary prevention.
Death rates due to heart failure are increasing among younger adults under 65, with black men under age 65 facing the largest increase in premature death. The study found that an estimated 6 million adults in the US have heart failure, which is the number one reason older adults are admitted to hospital.
A recent survey reveals that nearly half of the public incorrectly believes heart failure is a normal part of aging, highlighting low awareness among both patients and the general public. Exercise has been found to be beneficial for patients with heart failure, with over half recognizing its potential as a treatment option.
A new study highlights the growing need for cardio-oncology services to monitor and prevent heart disease in cancer patients. The research found that many cancer survivors are not fully aware of the risks of cardiotoxicity and lack understanding of a balanced diet, making them more susceptible to heart failure.
A study presented at EuroHeartCare 2019 found that fitter heart failure patients have healthier brain function and are less likely to have cognitive impairment. Exercise has been shown to improve cognition in older adults and may also benefit heart failure patients.
Researchers have found that the drug Tadalafil, used to treat erectile dysfunction, slows or even reverses the progression of heart failure in sheep. The study suggests that the drug may also be effective in humans, offering new hope for treatment of this devastating condition.
A new study of 2.8 million UK adults found that higher BMI is associated with a significant increase in the risk of type 2 diabetes, sleep apnoea, heart failure, high blood pressure, and premature death. Adults with severe obesity class III are 12 times as likely to develop type 2 diabetes.
Researchers aim to understand molecular mechanisms behind dilative cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), two leading causes of heart failure. The study seeks to identify key genes and proteins involved in these conditions.
Researchers found a significant reduction in strokes and heart attacks with low-dose blood thinner use in patients with worsening heart failure or coronary artery disease. The study, published in JAMA Cardiology, suggests that this strategy may improve outcomes for patients at risk of subsequent issues.
A new study found that plant-based diets can lower the risk of heart failure in adults without known heart disease, while Southern diets are linked to higher risk. The study examined five dietary patterns and their association with incident heart failure hospitalizations.
Empagliflozin improved heart function, reduced pulmonary congestion, and enhanced systolic function in pigs with induced heart failure. The drug addressed heart failure by improving cardiac metabolism, boosting energy production and reducing glucose consumption.
A breakthrough treatment has been found to protect against kidney failure and cardiovascular complications in people with diabetes. The study showed a significant reduction in kidney failure and cardiovascular events, such as heart attacks and strokes, by up to 30%.
A team of UT Southwestern researchers has created a groundbreaking two-hit model to combat HFpEF, a type of heart failure with no effective treatments. By combining high-fat diets with blood pressure-raising drugs, they replicated the human condition and provided an accurate biological picture that can advance treatment development.
A combination of over-the-counter antioxidants shows promise for mitigating damaging effects of heart failure with preserved ejection fraction. Treatment improved markers of vascular function and inflammation in some patients, suggesting a simple and readily available option to improve vascular health.
A study found that heart failure patients are more likely to use the medication ivabradine when it is prescribed before hospital discharge. This can lead to a reduction in heart rate and improved outcomes. However, adoption of the therapy has been slow due to high cost and provider lack of familiarity.
A University of Guelph study found that the circadian mechanism affects cognition and mood in heart failure patients, suggesting ways to prevent and treat both conditions. The research may lead to new strategies to improve patients' quality of life.
A new study by NYU School of Medicine found that shorter stays in skilled nursing facilities (SNFs) are associated with a higher risk of hospital readmission among elderly heart failure patients. Patients who stayed at SNFs for two days or less had a risk four times higher than those who stayed longer.
Researchers at Ohio State University College of Medicine have identified a metabolic process in the heart that, if treated, could prevent or slow the progression of heart failure. By normalizing a reactive fat compound called acyl-CoA, the hearts retained their ability to burn fat and generate energy.
The CardioMEMS sensor reduced heart failure hospitalizations by 58% across all patient groups, including women and minorities. The device also lowered rates of all-cause hospitalizations for conditions like pneumonia and chronic obstructive pulmonary disease.
Researchers at UT Health San Antonio have created a smarter automatic defibrillator that accurately tracks stroke volume in addition to ECG readings. This update aims to deliver shocks only when needed, potentially preventing traumatic shocks and improving patient outcomes.
Patients with heart failure and a leaking heart valve who underwent transcatheter mitral valve repair reported significant improvements in quality of life after two years. The study found that patients treated with the procedure had better rates of survival and fewer symptoms, leading to improved daily activities.
A new study by the European Society of Cardiology found that a more precise placement of the left ventricular lead improves cardiac resynchronisation therapy (CRT) outcomes. The trial compared two methods for positioning the lead and found an absolute increase in left ventricular ejection fraction of 4% with electrical guidance.
Dapagliflozin significantly decreases rates of death from cardiovascular causes and death from all causes among patients with reduced ejection fraction. It also reduces heart failure hospitalizations across all patients, regardless of ejection fraction or heart failure status.
A recent study found that remote monitoring of implanted defibrillators in heart failure patients significantly reduces the rate of hospitalization and death. The trial showed a lower rate of primary endpoint (39.5%) compared to standard care (48.5%), with reduced cardiovascular deaths and hospitalizations.
The HeartMate 3 left ventricular assist device (LVAD) significantly reduces strokes, pump-related blood clots, and bleeding episodes compared to the older HeartMate II. This trial enrolled 1,028 patients with advanced heart failure, showing a 40% reduction in risk favoring the HeartMate 3.
The final results of MOMENTUM 3 show that the HeartMate 3 left-ventricular assist device markedly reduced re-operation due to pump malfunctions, lowering risk of bleeding events and strokes. The study found significant reductions in pump-related thrombosis, strokes and mucosal bleeding compared to the previous generation of cardiac pumps.
A multidisciplinary team-based approach involving cardiac and maternal/fetal/newborn specialists saved the life of a pregnant woman with heart failure. The team successfully managed her care for seven weeks, delivering the baby prematurely but saving both mom and child.
The researchers developed a molecule called SAMβA that not only stabilizes but regresses heart failure in rats. The molecule improves the heart's capacity to pump blood and reduces oxidative stress in heart cells.
The study found that activity of the ActRII pathway increases with aging and heart failure, leading to cardiac dysfunction. Inhibiting this pathway can improve cardiac function in animal models of heart failure, suggesting a potential new treatment strategy for the deadly disease.
A study published in The BMJ found a genetic link between high testosterone levels and increased risk of blood clots, heart failure, and heart attacks in men. Researchers suggest that treatments lowering testosterone levels could help protect against these conditions, particularly in men.
A high-fat diet and aging are associated with inflammation in heart failure, as well as changes to the gut microbiome. In mice, a calorie-dense diet altered the composition of the gut microbiome and increased neutrophils, leading to nonresolving inflammation.
A study published in the Canadian Journal of Cardiology found that patients in Northern Ontario had higher hospital readmission rates for heart conditions, despite similar survival rates at 30 days. The researchers suggest providing timely transitional care and improving access to specialist care as key strategies to reduce readmissions.
This CVIA special issue addresses the #1 threat to women's health, cardiovascular disease, with a focus on overlooked topics and fresh perspectives. Key findings include novel imaging modalities for diagnosing stable ischemic heart disease in women and psychosocial stressors uniquely affecting female cardiovascular risk.
A study led by McMaster University found that providing additional health-care services to help heart failure patients transition from hospital to home does not improve their outcome. Despite this, patients receiving the intervention reported improvements in discharge preparedness and quality of life.
A large UK study found that heart failure survival rates have only improved modestly since 2000, with significant disparities in outcomes across different socioeconomic groups. The research highlights the need for increased investment in heart failure services to address these inequalities.
A personalized decision aid failed to help surrogate decision makers and clinicians agree on treatment goals for critically ill patients. Nearly all surrogates chose a more aggressive treatment goal despite the aid being based on their patient's values.
Scientists identify epigenetic marker and genes that cause heart failure in fruit fly offspring, even when fed a normal diet. Reversing the epigenetic modification or over-expressing these genes protects subsequent generations from negative heart effects.
Researchers have identified a key molecule named PI3K alpha that binds to gelsolin and suppresses its enzyme activity, leading to dilated cardiomyopathy. The discovery offers potential for targeted therapies in patients with heart failure.
A study found that standard assessment tools can accurately determine which residents are most at risk of hospitalization or death. Residents with a history of heart failure were more likely to be hospitalized and have higher mortality rates.
A new study by Tel Aviv University reveals that a functional heart cell defect may be the underlying cause of peripartum cardiomyopathy (PPCM), a rare form of heart failure. The research found that levels of STAT3 protein were higher in PPCM patients' heart cells than in healthy women, and that a defect in releasing growth factors was ...
A study suggests that older adults with newly diagnosed heart failure can continue to drink moderate amounts without worsening their condition. Moderate drinkers had an average survival benefit of over a year longer than abstainers.
A study of 393 patients found that limited alcohol consumption was associated with increased survival, with an average additional year of life at 383 days compared to abstinence. However, the optimal levels of alcohol consumption for adults with heart failure remain unknown.
A meta-analysis of randomized controlled trials found catheter ablation superior to conventional drug therapy for patients with atrial fibrillation and heart failure. The procedure was associated with reduced all-cause mortality, heart failure hospitalizations, and improved quality of life.